OpenAI's GPT‑Rosalind model, designed for chemistry and genomics, demonstrates superior performance on scientific benchmarks, outperforms human experts, offers a rich plugin ecosystem, and implements strict access controls to help accelerate early-stage drug research while ensuring responsible AI use in life sciences.
On March 20 2026, Alibaba’s Qwen 3.5‑Max topped the LMArena blind‑test, OpenAI bought Astral to boost AI coding, Zhejiang University released a real‑time 4D world model, Meta’s Agent leaked data, and a series of AI‑driven innovations from Nvidia, robotics to drug discovery reshaped the industry.
A German research team integrated protein sequences, domain architectures, 3D structures, functional annotations and expression profiles to build a multi‑scale, metric‑learning classification of the human E3 ubiquitin ligase repertoire, revealing family hierarchies, essential enzymes for cell viability and new drug‑target opportunities.
This article explores how AI-driven models and data pipelines are transforming the chemistry and pharmaceutical sectors by accelerating drug design, improving protein‑antibody predictions, automating patent data extraction, and outlining future goals for end‑to‑end AI‑enabled scientific discovery.
Recent MIT research demonstrates that a generative AI model trained on massive antibacterial datasets can design millions of novel molecules, with several candidates showing potent activity in mouse models, highlighting AI’s shift from discovery to de novo drug design.
A University of Pennsylvania team built a global venom database, applied the deep‑learning APEX model to predict antimicrobial activity across 34 bacterial strains, screened 4 × 10⁷ encrypted peptides, and experimentally validated 386 novel candidates with a 91.4% success rate, offering a new avenue against antibiotic resistance.
The article explains how quantum computing, with its qubit superposition and exponential speed‑up, is reshaping IT hardware and software, enabling breakthroughs in drug discovery, finance, AI, and secure communications while facing commercialization challenges such as high costs and talent gaps.
DeepPurpose, a PyTorch‑based AI toolkit developed by Harvard researchers, provides COVID‑19 bioassay data and 56 cutting‑edge models that enable rapid drug‑target affinity prediction, virtual screening, and drug repurposing with just a few lines of code, dramatically shortening new‑drug development cycles.
AlphaFold 3, released by DeepMind in May 2024, dramatically speeds protein and biomolecule structure prediction, prompting predictions of a future Nobel Prize, while China’s HelixFold 3, the first domestic model matching AlphaFold 3’s performance, offers high‑accuracy, cloud‑based services for diverse molecular interactions and drug discovery.
The AI4R&D report released on July 25 2024 outlines how artificial‑intelligence technologies are reshaping scientific research and industrial development by boosting computing power, data utilization and toolchains, delivering breakthroughs in drug discovery, materials and simulation, and mapping an emerging ecosystem that promises faster translation of innovation into practical applications.
This weekly tech roundup covers Microsoft’s upcoming mobile game store, Alibaba Cloud’s Tongyi Qianwen 2.5 AI model, Google DeepMind’s AlphaFold 3 for drug discovery, TikTok’s AI‑content labeling, 神州信息’s AI‑native product, Apple’s on‑device AI chips, expert views on scaling laws, and news on Fei‑Fei Li’s startup, Apple’s China tax, and Buffett’s Apple stake reduction.
In his 2024 outlook, Bill Gates emphasizes that artificial intelligence will be a pivotal force this year, driving breakthroughs in drug discovery, combating antibiotic resistance, personalizing education, improving maternal health, and expanding access to HIV risk assessment and medical information for underserved populations.
Insilico Medicine, leveraging artificial intelligence to identify a novel target and molecule for idiopathic pulmonary fibrosis, has advanced its AI-discovered drug into late-stage clinical trials, marking the first fully AI-generated pre-clinical candidate and drawing significant attention from the pharmaceutical industry.
This article reviews the development of AIGC and generative AI technologies—including image, text, and molecular generation—explains key model advances such as diffusion and large language models, discusses their impact on drug discovery, and outlines current challenges, opportunities, and future directions.
This article reviews global trends in AI‑driven biopharma, outlines the technical challenges, and details Baidu Intelligent Cloud’s bio‑computing large‑model technologies—including HelixGEM, HelixFold, and HelixFold‑Single—along with their industrial applications in drug design, protein prediction, and mRNA vaccine development.
This article presents a comprehensive overview of using geometric graph neural networks on the Baidu PaddleHelix platform to address challenges in drug discovery, including 3D‑structure‑aware protein‑ligand binding affinity prediction, molecular property prediction, and self‑supervised pre‑training, with experimental results showing significant improvements over existing baselines.
This article reviews the motivation, methods, and results of graph-based self‑supervised pretraining for molecular data, introduces the ChemRL‑GEM model that incorporates 3‑D structural information, and demonstrates its superior performance on ADMET, affinity prediction, and benchmark competitions using the PaddleHelix platform.
This talk by Huawei senior engineer Xu Chi explores the challenges of drug screening, AI-driven drug discovery practices, and how personalized federated learning combined with Huawei Cloud's high‑performance computing accelerates pharmaceutical research, including case studies, platform services, and collaborative efforts.
Graph Neural Networks (GNNs) are increasingly applied in biochemistry, enabling molecular property prediction, chemical reaction forecasting, molecular graph generation, and drug–protein interaction modeling, with various generative models such as GraphRNN, MolGAN, VAE, and flow-based approaches enhancing drug discovery pipelines.
This article explains how Alibaba Cloud's E‑HPC supercomputing platform provides the massive compute power needed for rapid virus research and high‑throughput drug screening, detailing the workflow, required resources, and practical code examples for parallel processing in the fight against COVID‑19.
This article explores how algorithms, particularly AI and genetic algorithms, are applied across diverse fields such as advertising, social issue resolution, drug discovery, and public welfare, highlighting their transformative impact on technology and society.
